Metastasis to the skeleton is common in advanced renal cancer and leads to debilitating
skeletal complications including severe pain, increased fracture rate and spinal cord …

Despite offering significant clinical benefits in advanced renal-cell carcinoma (RCC), the
effectiveness of targeted therapies eventually declines with the development of resistance …

Background In a phase II study of axitinib for cytokine-refractory metastatic renal cell
carcinoma, median overall survival (OS) was 29.9 months (95% CI, 20.3 to not estimable …

Abstract Purpose Skeletal-related events (SREs) negatively affect the quality of life of
patients with cancer. Vascular endothelial growth factor receptor (VEGFR)-targeted therapy …

Therapy of patients with metastatic renal cell carcinoma (mRCC) requires sequential use of
several agents with different mechanisms and minimal cross-resistance between the …

In practice it is still not clear whether a drug holiday in sunitinib (Su) treatment can be safety,
without impairing the overall outcome of patients with metastatic renal cell carcinoma …

It is a case study of female patient aged 69 years known with no significant family history of
malignancies, diagnosed on July 2012 with a 6 th cervical vertebral body voluminous mass …

A primer vesedaganatok 80-90%-a vesesejtes karcinóma (RCC), aminek kiindulási pontja a
vese kéregállománya. A RCC leggyakoribb szövettani típusa a világossejtes RCC (70 …

Abstract Purpose: Skeletal-related events (SREs) negatively affect the quality of life of
patients with cancer. Vascular endothelial growth factor receptor (VEGFR)-targeted therapy …

目的: 探讨苹果酸舒尼替尼对晚期肾细胞癌治疗的安全性和有效性. 方法: 晚期肾细胞癌患者22
例, 男18 例, 女4 例, 平均年龄56 岁, 均为转移性或难以手术的肾细胞癌患者. 采用舒尼替尼治疗 …